▲美登素及其衍生物的结构
01
作用机制
▲ 微管蛋白聚合和解聚的动力学
02
应用
理化性质
DM1 常温常压下为固体,能溶解于常见的有机溶剂例如乙酸乙酯,二氯甲烷以及醇类溶剂等,但是在醚类溶剂和水中溶解性差。需要注意的是,在溶液状态不稳定,建议现用现配。
03
文献精选
文章标题:Endoplasmic reticulum-targeted glutathione and pH dual responsive vitamin lipid nanovesicles for tocopheryl DM1 delivery and cancer therapy
▲ 点击图片跳转原文
研究概览:研究中首次合成了一种生育酚-DM1,在低 pH 插入肽(pHLIP)锚定的维生素脂质纳米囊泡中进行了封装。这一设计巧妙地结合了脂质-药物共轭物和抗体药物偶联物(ADCs)的优势,实现了对癌细胞的精准靶向,显著增强了癌症治疗的效果。
文章标题:Self-assembling mertansine prodrug improves tolerability and efficacy of chemotherapy against metastatic triple-negative breast cancer
▲ 点击图片跳转原文
研究概览:研究报道了一种创新的自组装肽-药物共轭物,由亲水性肽和 mertansine 通过二硫键连接而成。首次对 mertansine 前药的自组装进行了深入研究,并进一步探讨了形成的自组装 mertansine 前药(SAMPD)与体外和体内的癌细胞以及器官的相互作用。这一新型构建可显著改善 mertansine 对转移性三阴性乳腺癌(TNBC)的耐受性和治疗效果。
文章标题:Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy
▲ 点击图片跳转原文
研究概览:研究团队成功构建了基于 5D3 mAb 和 mertansine 的抗体药物偶联物(ADC),并对其在体外的结合亲和力、内化和细胞毒性进行了评估。随后,他们在人类前列腺癌小鼠模型中验证了 5D3-DM1 ADC的治疗效果,揭示了这种新型抗-PSMA ADC 能够有效控制 PSMA(+) 肿瘤的生长,同时不引起全身毒性。
参考文献:
[1] Yu-Qing Wang, Meng-Ying Ji, Chang Wang,Endoplasmic reticulum-targeted glutathione and pH dual responsive vitamin lipid nanovesicles for tocopheryl DM1 delivery and cancer therapy,International Journal of Pharmaceutics,Volume 582,2020,119331,ISSN 0378-5173.
[2] Huang CT, Guo X, Bařinka C, et al. Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy. Mol Pharm. 2020;17(9):3392-3402. doi:10.1021/acs.molpharmaceut.0c00457
[3] Ran W, Liu X, Chang L, et al. Self-assembling mertansine prodrug improves tolerability and efficacy of chemotherapy against metastatic triple-negative breast cancer. J Control Release. 2020;318:234-245. doi:10.1016/j.jconrel.2019.12.027
[4] Liliana Ascione, Edoardo Crimini, Dario Trapani, Antonio Marra, Carmen Criscitiello, Giuseppe Curigliano, Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability, The Oncologist, Volume 28, Issue 11, November 2023, Pages 944–960, https://doi.org/10.1093/oncolo/oyad246